Rui Therapeutics

Rui Therapeutics is a platform company focused on the research and development of next-generation cell-based drugs. Founded by returning overseas scientists and senior executives from multinational pharmaceutical companies, the company is committed to innovating its proprietary core technologies. Rui Therapeutics has established three platforms in the field of cell therapy: first, the CAR-NK platform; second, the single-base gene editing platform; third, the small molecule-induced differentiation iPSC platform. With a focus on inventive innovation, the company has developed proprietary core technologies, such as CAR structure design technology for CAR-NK development, the HTAS-RVTM viral delivery system, and the CRA-NKTM domestication technology. Currently, the company has laid out cutting-edge First-in-class pipeline products, covering tumors, autoimmune diseases, central nervous system disorders, and anti-aging fields where clinical needs remain unmet.